AngioDynamics Reports $10.9M Net Loss and 12.2% Revenue Growth in Q1 FY 2026

AngioDynamics, Inc. reported a net loss of $10.9 million for the first quarter of fiscal year 2026, a decrease from a net loss of $12.8 million in the same period last year. The company’s revenue increased by 12.2% to $75.7 million, compared to $67.5 million in the prior year. This growth was driven by a 26.1% increase in the Med Tech segment, which includes products like Auryon and NanoKnife, and a 2.3% increase in the Med Device segment. The gross margin improved to 55.3%, up from 54.4% in the previous year, reflecting better sales volume and product mix.

In terms of operational metrics, AngioDynamics saw significant growth in its Med Tech segment, with net sales rising by $7.3 million, primarily due to increased sales of Auryon and thrombus management products. The Med Device segment also contributed with a $0.9 million increase in sales, driven by growth in Core and Venous product lines, although this was partially offset by declines in Ports and Microwave products. The company’s international sales accounted for 12.2% of total net sales, reflecting a slight increase from 11.9% in the previous year.

AngioDynamics has been actively managing its operational costs, with total operating expenses rising to $52.5 million from $49.8 million year-over-year. The increase was attributed to higher sales and marketing expenses, which rose by $2.5 million, and general and administrative expenses, which increased by $1.6 million. Research and development expenses remained relatively stable, increasing slightly to $6.4 million. The company continues to focus on strategic initiatives, including a restructuring plan aimed at optimizing its manufacturing capabilities, which is expected to be completed by the third quarter of fiscal year 2026.

As of August 31, 2025, AngioDynamics had cash and cash equivalents of $38.8 million, down from $55.9 million at the end of the previous fiscal year. The company reported cash used in operating activities of $15.9 million, which was an improvement from $18.3 million in the prior year. The decrease in cash was primarily due to changes in working capital, including a reduction in accounts payable and accrued liabilities. Looking ahead, AngioDynamics remains focused on expanding its product offerings and geographic reach, while navigating challenges such as supply chain reliability and inflationary pressures. The company believes its current cash position, along with cash generated from operations, will provide sufficient liquidity for the next 12 months.